Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

Rhea-AI Summary

Femasys Inc. (Nasdaq: FEMY) will exhibit at the Canadian Fertility and Andrology Society's 70th Annual Meeting from September 12-14, 2024, in Vancouver. The company, focused on women's health, will showcase its portfolio of infertility products, including the recently Canadian-approved FemVue MINI, an eco-friendly fallopian tube assessment solution, and FemaSeed, a next-generation artificial insemination product.

CEO Kathy-Lee Sepsick highlighted the importance of connecting with practitioners whose patients could benefit from Femasys' suite of products. The FemVue MINI maintains the efficacy of its predecessor while embracing an eco-conscious design, aiming to improve resource management in women's healthcare. This Canadian approval is expected to expand access to advanced diagnostic technology for women across the country.

Positive

• Recent Canadian approval of FemVue MINI, expanding market reach
• Opportunity to showcase products to potential customers at CFAS Annual Meeting
• FemVue MINI offers eco-friendly design while maintaining efficacy

Negative

• None.

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society’s (CFAS) 70^th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.

Kathy-Lee Sepsick, Femasys Founder and CEO commented, “This is an important opportunity to connect with practitioners whose patients and clients would benefit from our suite of products. The conference comes at a particularly opportune moment as we recently announced the Canadian approval of FemVue MINI, our eco-friendly version of our solution for fallopian tube assessment. We continue to advance solutions to improve women’s reproductive health worldwide and look forward to demonstrating our portfolio of infertility products, including FemVue^® MINI and FemaSeed^®, our next generation artificial insemination product to potential customers.”

The CFAS is a multidisciplinary national non-profit society that serves as the voice of reproductive specialists including physicians, nurses, andrologists, embryologists, research scientists, counsellors, psychologists, social workers, lawyers, ethicists, administrative professionals and trainees working in the field of Assisted Reproduction in Canada. Established in 1954, the mission of the CFAS is to responsibly advance reproductive science and medicine in Canada through leadership, research, and guidance. Through its 700 multidisciplinary memberships, the CFAS aims to promote excellence in the field of Assisted Reproduction to the benefit of Canadians and children born of this technology.

The FemVue MINI is designed to provide the same high level of efficacy as its predecessor while embracing an eco-conscious form factor. By optimizing the size and environmental impact of FemVue, the Company aims to make a significant positive difference in resource management within women’s health care. The Canadian approval of FemVue MINI opens new opportunities for expanded access to advanced diagnostic technology for women across Canada.

About Femasys

Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed^® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc^® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue^® and FemVue^® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath^®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv^®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

Forward-Looking Statements 

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. 

Contacts: 

Investors: 
CORE IR
Matt Blaise
IR@femasys.com

Media:
CORE IR 
Kati Waldenburg
Media@femasys.com

FAQ

What products will Femasys (FEMY) showcase at the CFAS 70th Annual Meeting in 2024?

Femasys (FEMY) will showcase its portfolio of infertility products, including the recently Canadian-approved FemVue MINI, an eco-friendly fallopian tube assessment solution, and FemaSeed, a next-generation artificial insemination product.

When and where will the Canadian Fertility and Andrology Society's 70th Annual Meeting take place?

The Canadian Fertility and Andrology Society's 70th Annual Meeting will be held from September 12-14, 2024, at The Westin Bayshore in Vancouver, British Columbia.

What is the significance of the FemVue MINI's Canadian approval for Femasys (FEMY)?

The Canadian approval of FemVue MINI opens new opportunities for Femasys (FEMY) to expand access to advanced diagnostic technology for women across Canada, potentially increasing the company's market reach and product adoption.

How does the FemVue MINI differ from its predecessor?

The FemVue MINI is designed to provide the same high level of efficacy as its predecessor while embracing an eco-conscious form factor. It aims to make a significant positive difference in resource management within women's health care by optimizing size and environmental impact.